Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 84

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 84
---
 a timely basis or at all; |

| • |     | the costs involved in connection with negotiating and entering into the Merger Agreement and consummating the                                                                                                                     
 Merger, and the substantial time and effort of management required to consummate the Merger and related disruptions to the operation of STAAR’s business (including certain costs and expenses if the Merger is not consummated); |

| • |     | the risk that the expiration or termination of the waiting period under the HSR Act or other required regulatory                                                                                                                              
 approvals, which are required for the consummation of the Merger, may not be obtained or that regulators may require divestitures or other remedies, and the fact that Alcon’s commitment to agree to any such remedies is subject to certain 
 limitations;                                                                                                                                                                                                                                  |

| • |     | the fact that the announcement and pendency of the transactions contemplated by the Merger Agreement, the failure                                                                                                                                       
 to consummate the Merger or actions that STAAR may be required, or Alcon may be permitted, to take under the Merger Agreement could have an adverse impact on existing and prospective business relationships with distributors, customers, suppliers,  
 employees, partners or other business relationships, including the risk that certain key members of STAAR management might choose not to remain employed with STAAR prior to the consummation of the Merger, regardless of whether or not the Merger is 
 consummated;                                                                                                                                                                                                                                            |

| • |     | the fact that STAAR’s stockholders will have no ongoing equity participation in STAAR following the Merger,                                                                                                                                         
 and will cease to participate in STAAR’s future earnings and growth, if any, and will not benefit from increases, if any, in the value of STAAR following the Merger, and the possibility that, although the Merger provides STAAR stockholders the 
 opportunity to realize a significant premium to                                                                                                                                                                                                     |

-51-

| the price at which STAAR common stock traded prior to announcement of the Merger, the price of STAAR common stock might have increased in the future to a price greater than the Merger 
 Consideration;                                                                                                                                                                          |

| • |     | the fact that shares of STAAR common stock traded at a price higher than the per share Merger Consideration of 
 $28.00 as recently as December 3, 2024;                                                                        |

| • |     | as described in the section of this proxy statement titled “—Background of the Merger,”